We integrated in vitro and in vivo functional assays, RNA sequencing, clinical, and expression information from public data sets to investigate the role of ADAM23 expression coupling astrocytoma’s growth and motility. This evidence concerns the gene ADAM23 and astrocytoma (excluding glioblastoma).